DLL4 and breast cancer: Blocking Dll4, the Notch ligand specifically involved in modulation of angiogenesis, has given promising results in interfering with cancer growth: administration of anti-Dll4 agents in breast cancer xenografts promotes excessive sprouting, which leads to unproductive angiogenesis (48).